Palladon Injectie (Hydromorphone Hydrochloride)

Palladon Injectie contains hydromorphone, an opioid that acts on the central nervous system to relieve pain. It is indicated for:

• Post‑operative pain: provides rapid, controllable analgesia after surgery.
• Cancer‑related pain: helps manage moderate to severe pain in oncology patients.
• Acute severe pain: used when fast onset of relief is required, such as in trauma or severe injury.
• Chronic pain requiring opioid rotation: may be employed when switching from another opioid to maintain analgesic control.

• Hydromorphone hydrochloride binds selectively to μ‑opioid receptors in the central nervous system, mimicking endogenous opioids. This activation reduces neuronal excitability and inhibits the transmission of nociceptive signals, producing analgesia and a sense of well‑being. The drug’s high affinity for the μ‑receptor accounts for its potency relative to morphine.

Hydromorphone may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects

• Nausea and vomiting: frequent gastrointestinal response.
• Constipation: reduced bowel motility.
• Drowsiness or sedation: central nervous system depression.
• Dry mouth: decreased salivation.
• Pruritus: itching, often localized.
• Dizziness: light‑headed sensation.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing.
• Severe hypotension: marked drop in blood pressure.
• Bradycardia: unusually slow heart rate.
• Allergic reactions: rash, swelling, or anaphylaxis.
• Urinary retention: difficulty emptying the bladder.
• Seizures: rare neurologic events.

When using Palladon Injectie, clinicians should observe several safety measures.

• Assess pain level and opioid tolerance: tailor dosing to individual needs.
• Monitor respiratory function: watch for signs of depression, especially after initiation.
• Evaluate renal and hepatic function: adjust use in impairment.
• Avoid concurrent CNS depressants: limit additive sedation risk.
• Educate patients on dependence potential: discuss safe use and storage.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Hydromorphone can interact with various medications, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Benzodiazepines: combined use can cause profound respiratory depression.
• Barbiturates: additive central nervous system depression.
• Muscle relaxants: increased risk of sedation and respiratory compromise.

Moderate Interactions (Monitor Closely)

• Anticholinergics: may worsen constipation.
• CYP3A4 inhibitors (e.g., ketoconazole): can raise hydromorphone plasma levels.
• CYP3A4 inducers (e.g., rifampicin): may reduce analgesic effect.